Categories

Tag: Recursion Pharmaceuticals

The Mid-term Elections Will Not Resolve the Dysfunction at HHS

By STEVEN ZECOLA

Introduction.

The scientists at the Department of Health and Human Services (“HHS”) are breathing a sigh of relief given that the Democrats will be taking control of the House and Senate. For the past two years, there has been a tension within HHS between the scientific community and President Trump’s executive appointments. While Trump’s people have been “winning” the political battles over vaccines and restrictions on abortion-related treatments, they have not made much progress on modernizing the drug approval process, despite repeated promises. The approval process for promising therapies remains slow, uncertain, and resistant to change.

Managing by Press Release

Over the past year, HHS and FDA have announced initiatives involving personalized gene therapies, rare-disease development, AI-enabled healthcare, real-time clinical trials, and regulatory modernization.

Collectively, these announcements convey an agency committed to accelerating innovation. The more important issue for the public is whether these initiatives are changing how therapies move through the approval process.

From Promises to Practice

To judge whether reform is occurring, it is necessary to examine actual regulatory outcomes rather than public statements.

First, the FDA has had data for over a year showing how an innovative therapy for familial adenomatous polyposis (FAP) improves patient outcomes with minimum risk.

FAP is a genetic disorder that predisposes people to develop precancerous colon polyps. With FAP, patients will develop many colon polyps — typically over a hundred — starting at a young age. This significantly raises the lifetime risk that one of them will become cancerous. To manage this risk, healthcare providers usually recommend complete removal of the colon and sometimes the rectum, as well.

Continue reading…